| Literature DB >> 32214425 |
N Sh Nadaraia1, N N Barbakadze1, M L Kakhabrishvili1, B Sylla2, A Pichette2, U S Makhmudov3.
Abstract
Several new N-containing epiandrosterone derivatives modified by phenylacetic acid chloride were synthesized for biological activity studies. Compounds with antiviral activity were discovered among them and 3β-hydroxy-1'-aryl-3'-methyl-5'-androstano[17,16-d]pyrazolines prepared by us earlier. © Springer Science+Business Media, LLC, part of Springer Nature 2018.Entities:
Keywords: antiviral activity; epiandrosterone; hydrazones; modification; phenylacetic acid; pyrazolines
Year: 2018 PMID: 32214425 PMCID: PMC7087839 DOI: 10.1007/s10600-018-2330-2
Source DB: PubMed Journal: Chem Nat Compd ISSN: 0009-3130 Impact factor: 0.809
Fig. 1.Molecular structure of 2.
Main Crystallographic and X-ray Structure Analysis Parameters for 2
| Parameter |
| Parameter |
|
|---|---|---|---|
| Molecular formula | C27H36O3 | ρ, g/cm3 | 1.184 |
| MM, g/mol | 408.6 | Crystal size, mm | 0.3 × 0.4 × 00.4 |
| System | Orthorhombic | Scan range | 3.31≤ θ ≤75.78 |
| Space group | P 212121 | μexp, cm–1 | 0.587 |
| Z | 4 | Number of reflections | 3907 |
| 6.1398 (2) | Number of reflections with I > 2σ(I) | 2884 | |
| 16.5469 (5) | R1 (I > 2σ (I) and total) | 0.0485 (0.0668) | |
| 22.5683 (8) | WR2 | 0.1250 (0.1388) | |
| α | 90.00 | GOOF | 0.868 |
| β | 90.00 | Electron-density difference peaks (e Å–3) | 0.13 and –0.16 |
| γ | 90.00 | CCDC | 1570849 |
| 2292.8 (2) |
Data for in vitro Screening of Antiviral Activity of 3–7 and 9–12
| Compound | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| c | CC50 | Sl50 | EC50 | CC50 | Sl50 | EC50 | CC50 | Sl50 | EC50 | CC50 | Sl50 | |
| Visual (cytopathic effect/toxicity) | ||||||||||||
|
| 2.8 | 3.2 | 1.1 | >3.2 | 3.2 | 0 | 3.2 | 8.6 | 2.7 | 3.2 | 3.2 | 1 |
|
| 0.32 | 100 | 310 | 3.2 | 15 | 4.7 | 31 | 68 | 2.2 | 31 | 46 | 1.5 |
|
| 1 | 10 | 10 | 6.8 | 32 | 4.7 | 3.2 | 13 | 4.1 | 3.2 | 15 | 4.7 |
|
| 22 | 100 | 4.5 | >32 | 32 | 0 | >100 | >100 | 0 | 32 | 42 | 1.3 |
|
| 3.4 | 12 | 3.5 | 3.7 | 28 | 7.6 | 3.2 | 5.6 | 1.8 | >13 | 13 | 0 |
|
| 3.2 | 22 | 6.9 | >5.2 | 5.2 | 0 | 1.8 | 12 | 6.7 | 12 | 24 | 2 |
|
| 2.4 | >100 | >42 | >28 | 28 | 0 | 1.9 | 14 | 7.4 | >30 | 30 | 0 |
|
| 32 | >100 | >3.1 | >32 | 32 | 0 | >100 | >100 | 0 | >100 | >100 | 0 |
|
| 0.32 | 10 | 31 | >19 | 19 | 0 | 3.2 | 10 | 3.1 | 5 | 18 | 3.6 |
| Control | 0.32 | >10 | >31 | 0.68 | >100 | >150 | 6.8 | >1000 | >150 | 6.5 | >1000 | >150 |
| Neutral red (cytopathic effect/toxicity) | ||||||||||||
|
| 2.8 | 3.6 | 1.3 | >4.3 | 4.3 | 0 | 6.6 | 7.5 | 1.1 | >4.8 | 4.8 | 0 |
|
| 0.35 | >100 | >290 | 4.6 | 24 | 5.2 | >56 | 56 | 0 | >32 | 32 | 0 |
|
| 0.52 | 20 | 38 | 2.2 | 21 | 9.5 | 1.2 | 5.2 | 4.3 | 4.1 | 18 | 4.4 |
|
| 92 | >100 | >1.1 | >100 | >100 | 0 | >100 | >100 | 0 | >100 | >100 | 0 |
|
| 7 | 26 | 3.7 | >17 | 17 | 0 | 3.2 | 3.9 | 1.2 | >24 | 24 | 0 |
|
| 2.2 | 100 | 45 | >28 | 28 | 0 | 1.7 | 14 | 8.2 | 25 | 28 | 1.1 |
|
| 3.1 | 15 | 4.8 | 3.2 | 4.5 | 1.4 | 2.3 | 14 | 6.1 | 12 | 27 | 2.3 |
|
| 30 | >100 | >3.3 | 36 | 63 | 1.8 | >100 | >100 | 0 | >100 | >100 | 0 |
|
| 0.28 | 19 | 68 | >5.5 | 5.5 | 0 | 2.8 | 5 | 1.8 | 7 | 20 | 2.9 |
| Control | 0.3 | >10 | >33 | 1.8 | >100 | >56 | 8.6 | >1000 | >120 | 7.1 | >1000 | >140 |
EC50 is the compound concentration inhibiting virus replication by 50%; CC50, compound concentration reducing cell survival by 50%; SI50 = CC50/EC50.